Foghorn Therapeutics (NASDAQ: FHTX) revenue
Foghorn Therapeutics reported revenue of $30.9m for fiscal 2025, 36.8% more than in fiscal 2024 ($22.6m). Since fiscal 2020 its revenue has grown by 7,088.1%, an average growth of 135.1% a year.
Foghorn Therapeutics's best year of the last 6 was fiscal 2023. The biggest drop was in fiscal 2024, −33.8%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $30.9m | +36.8% | −$86.4m | −279.5% |
| 2024 | $22.6m | −33.8% | −$102.7m | −454.3% |
| 2023 | $34.2m | +77.6% | −$107.9m | −315.9% |
| 2022 | $19.2m | +1,357.8% | −$117.1m | −609.2% |
| 2021 | $1.3m | +206.7% | −$100.7m | −7,637.1% |
| 2020 | $0.4m | — | −$68.5m | −15,937.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Foghorn Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Foghorn Therapeutics ranks 351st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Foghorn Therapeutics, 36.8%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 349th | EyePoint | $31.4m | −27.5% |
| 350th | Verastem | $30.9m | 209.1% |
| 351st | Foghorn Therapeutics | $30.9m | 36.8% |
| 352nd | Entrada Therapeutics | $25.4m | −87.9% |
| 353rd | Alumis | $24.1m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Foghorn Therapeutics
- How much revenue did Foghorn Therapeutics make in fiscal 2025?
- Foghorn Therapeutics reported revenue of $30.9m for fiscal 2025, compared with $22.6m in fiscal 2024.
- How much has the revenue of Foghorn Therapeutics grown?
- Between fiscal 2020 and fiscal 2025 it went from $0.4m to $30.9m: 7,088.1% more, an average growth of 135.1% a year.
- What was the best year for revenue at Foghorn Therapeutics?
- Of its last 6 fiscal years, fiscal 2023, with $34.2m.
- Where does Foghorn Therapeutics rank in its sector by revenue?
- It ranks 351st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Foghorn Therapeutics come from?
- From the annual report (Form 10-K) that Foghorn Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Foghorn Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Foghorn Therapeutics: the Foghorn Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.